R
Rimas J. Orentas
Researcher at University of Washington
Publications - 116
Citations - 9516
Rimas J. Orentas is an academic researcher from University of Washington. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 33, co-authored 94 publications receiving 7302 citations. Previous affiliations of Rimas J. Orentas include Medical College of Wisconsin & Miltenyi Biotec.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long,Waleed Haso,Jack F. Shern,Kelsey Wanhainen,Meera Murgai,Maria Ingaramo,Jillian P. Smith,Alec J. Walker,M. Eric Kohler,Vikas R Venkateshwara,Rosandra N. Kaplan,George H. Patterson,Terry J. Fry,Rimas J. Orentas,Crystal L. Mackall +14 more
TL;DR: It is shown that tonic CAR CD3-ζ phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy, and that CD28 costimulation augments, whereas 4-1BB costimulations reduces, exhaustion induced by persistent CAR signaling.
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso,Daniel W. Lee,Nirali N. Shah,Maryalice Stetler-Stevenson,Constance M. Yuan,Ira Pastan,Dimiter S. Dimitrov,Richard A. Morgan,David J. FitzGerald,David M. Barrett,Alan S. Wayne,Alan S. Wayne,Crystal L. Mackall,Rimas J. Orentas +13 more
TL;DR: It is concluded that second-generation m971 mAb-derived anti-CD22 CARs are promising novel therapeutics that should be tested in BCP-ALL.
Journal ArticleDOI
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Robbie G. Majzner,Johanna Theruvath,Anandani Nellan,Sabine Heitzeneder,Yongzhi Cui,Christopher Mount,Skyler P. Rietberg,Miles H. Linde,Peng Xu,Christopher Rota,Elena Sotillo,Louai Labanieh,Daniel W. Lee,Rimas J. Orentas,Dimiter S. Dimitrov,Zhongyu Zhu,Brad St. Croix,Alberto Delaidelli,Alberto Delaidelli,Alla Sekunova,Alla Sekunova,Ezio Bonvini,Siddhartha Mitra,Siddhartha Mitra,Martha Quezado,Ravindra Majeti,Michelle Monje,Poul H. Sorensen,Poul H. Sorensen,John M. Maris,Crystal L. Mackall +30 more
TL;DR: B7-H3 CAR T-cell efficacy is largely dependent upon high surface target antigen density on tumor tissues and that activity is greatly diminished against target cells that express low levels of antigen, thus providing a possible therapeutic window despite low-level normal tissue expression of B7- H3.